Before You Spend Another £100,000 on Growth, Read This

• by Rod Solar

• August 6, 2026

Can Patients Switch to Biosimilar Aflibercept?

A 20-week INSIGHT extension suggests that switching from reference aflibercept to MYL-1701P maintained comparable safety, visual, and anatomic outcomes in patients with diabetic macular edema.

• by Andrea Surnit

• July 20, 2026

• 3 min

Systemic factors associated with poor anatomical response to anti-VEGF therapy in patients with diabetic macular edema: evidence from a large clinical cohort

• by Xinru Jia, Yan Shi, Mengxiang He, Dongwei Yao, Chengfei Lin

• July 21, 2026

Erucamide and the Degenerating Retina

Fatty acid amide could offer a new route for retinal rescue, says study

• August 5, 2026

• 3 min